22nd Century Group (NYSEAMERICAN: XXII) stock rose by 105% so far this year. This leading plant biotechnology company is advancing commercial opportunities across $1.3 trillion global addressable markets in tobacco, cannabis, and a third plant-based franchise. Although its current sales revenue is small, the future potential is huge.

Currently, securing modified risk tobacco product authorization for VLN remains the company's number one priority, and VLN is under review by FDA. This tobacco product is made exclusively from the company’s proprietary reduced-nicotine tobacco with at least 95% less nicotine as compared to conventional cigarettes. According to the Centers for Disease Control and Prevention, 80% of U.S. adult cigarette smokers favor requiring cigarette makers to reduce nicotine levels in cigarettes, so they are less addictive.

Looking to the future of the company. If VLN is approved by FDA, the company will quickly commence to commercialize this tobacco brand, and willing to license its reduced nicotine tobacco technology to every cigarette manufacturer to produce more cigarettes for smokers for being less addictive. Of course, this will also increase the company's revenue.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.